Morgan Stanley maintains a "overweight" rating on GUSHENGTANG(02273) with a target price of 62 Hong Kong dollars.
Currently, private hospitals are not required to participate in volume-based procurement. The company expects the group to achieve a revenue growth of over 20% this year, with a profit increase of over 25%.
Morgan Stanley released a research report stating that they are maintaining a "buy" rating for GUSHENGTANG (02273) with a target price of 62 Hong Kong dollars. Currently, private hospitals are not required to participate in volume-based procurement. The bank expects the group to achieve revenue growth of over 20% this year, with profit growth expected to be over 25%.
Related Articles
Huajin Securities: A-shares in June continue to fluctuate with a slight bias towards strength, the technology sector remains unchanged.
New Stock Outlook | Four major dividends boost performance release acceleration, can Ingenic Semiconductor (300223.SZ) go to Hong Kong for a "scarcity" price reevaluation?
Key NGS certificate terminated registration, facing a vacuum period of good news Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US) stock price fell more than 40% on the 5th.
Huajin Securities: A-shares in June continue to fluctuate with a slight bias towards strength, the technology sector remains unchanged.
New Stock Outlook | Four major dividends boost performance release acceleration, can Ingenic Semiconductor (300223.SZ) go to Hong Kong for a "scarcity" price reevaluation?
Key NGS certificate terminated registration, facing a vacuum period of good news Burning Rock Biotech Ltd. Sponsored ADR Class A (BNR.US) stock price fell more than 40% on the 5th.
